Inventor · disambiguated record
Haruka Okamoto
Also filed as: OKAMOTO HARUKA
20 granted patents·10 pending applications·119 citations·filing 2011–2025
94Inventor score
Files withREGENERON PHARMA27OKAMOTO HARUKA1REGENERAN PHARMACEUTICALS INC1SUMITOMO ELECTRIC INDUSTRIES1
Top patents by PatentIndex Score
30 records- 0196US9358287B2Method of treating stress hyperglycemia with human antibodies to the glucagon receptorREGENERON PHARMA·Filed 2014·Granted Jun 7, 2016·21 cites·10 claims
- 0295US9587029B2Human antibodies to the glucagon receptor and methods of use thereofREGENERON PHARMA·Filed 2015·Granted Mar 7, 2017·15 cites·19 claims
- 0394US9127068B2Nucleic acids encoding human glucagon receptor antibodiesREGENERON PHARMA·Filed 2013·Granted Sep 8, 2015·20 cites·10 claims
- 0494US8771696B2Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptorREGENERON PHARMA·Filed 2013·Granted Jul 8, 2014·12 cites·22 claims
- 0594US8545847B2Human antibodies to the human glucagon receptor and methods of use thereofOKAMOTO HARUKA·Filed 2011·Granted Oct 1, 2013·32 cites·17 claims
- 0692US11884736B2Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)REGENERON PHARMA·Filed 2021·Granted Jan 30, 2024·2 cites·12 claims
- 0792US11045522B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2018·Granted Jun 29, 2021·3 cites·5 claims
- 0891US9657099B2Anti-glucagon antibodiesREGENERON PHARMA·Filed 2015·Granted May 23, 2017·10 cites·14 claims
- 0988US10233250B2Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levelsREGENERON PHARMA·Filed 2017·Granted Mar 19, 2019·4 cites·21 claims
- 1087US12090193B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Granted Sep 17, 2024·0 cites·10 claims
- 1185US12269889B2Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levelsREGENERON PHARMA·Filed 2022·Granted Apr 8, 2025·0 cites·20 claims
- 1285US2025000949A1Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1380US2025304704A1Human antibodies to the glucagon receptorREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1478US2023416384A1Methods of treating severe insulin resistance by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1577US2025101119A1Methods of treating urea cycle disorders by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1676US11779633B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Oct 10, 2023·0 cites·5 claims
- 1775US12421317B2Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodiesREGENERON PHARMA·Filed 2023·Granted Sep 23, 2025·0 cites·15 claims
- 1873US11708416B2Methods of treating severe insulin resistance by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2021·Granted Jul 25, 2023·0 cites·11 claims
- 1973US11498970B2Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levelsREGENERON PHARMA·Filed 2020·Granted Nov 15, 2022·0 cites·11 claims
- 2073US10640566B2Nucleic acid molecules encoding antibodies to the human glucagon receptorREGENERON PHARMA·Filed 2019·Granted May 5, 2020·0 cites·10 claims
- 2166US12280124B2Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2021·Granted Apr 22, 2025·0 cites·33 claims
- 2266US2025171516A1Peptide acids as a glp1r agonist and antibody-drug conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2365US12139546B2Methods of treating urea cycle disorders by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2018·Granted Nov 12, 2024·0 cites·18 claims
- 2464US2023330254A1Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2563US10995146B2Methods of treating severe insulin resistance by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2017·Granted May 4, 2021·0 cites·11 claims
- 2659US2025161476A1Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2759US2016257757A1Method of treating stress hyperglycemia with human antibodies to the glucagon receptorREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 2852US12058812B2Substrate for a printed wiring boardSUMITOMO ELECTRIC INDUSTRIES·Filed 2021·Granted Aug 6, 2024·0 cites·9 claims
- 2948US2019248888A1Methods of lowering blood glucose levelsREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3048US2017218065A1Anti-glucagon antibodies and uses thereofREGENERON PHARMA·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Haruka Okamoto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →